Using Existing Drugs as Leads for Broad Spectrum Anthelmintics Targeting Protein Kinases

PLoS Pathogens

Volumn 9, Issue 2, 2013, Pages

  Taylor, Christina M ^a   Martin, John ^a   Rao, Ramakrishna U ^a   Powell, Kerrie ^b   Abubucker, Sahar ^a   Mitreva, Makedonka ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCYNEXIS Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CASEIN KINASE I; HELMINTH PROTEIN; HELMINTH RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; BRUGIA MALAYI; CAENORHABDITIS ELEGANS; DRUG EFFICACY; DRUG TARGETING; HAEMONCHUS CONTORTUS; PARASITISM;

ANIMALS; ANTHELMINTICS; BRUGIA MALAYI; CAENORHABDITIS ELEGANS; HAEMONCHUS; MOLECULAR STRUCTURE; PROTEIN KINASES; RNA INTERFERENCE;

EID: 84874780771     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003149     Document Type: Article

References (67)

1. Cohen P, (2001) The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 268: 5001-5010.
2. Boyle SN, Koleske AJ, (2007) Dissecting kinase signaling pathways. Drug Discov Today 12: 717-724.
3. Cohen P, (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315.
4. Manning G, (2005) Genomic overview of protein kinases. WormBook pp. 1-19.
5. Zhang J, Yang PL, Gray NS, (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
6. Cohen P, (2000) The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem Sci 25: 596-601.
7. Miranda-Saavedra D, Barton GJ, (2007) Classification and functional annotation of eukaryotic protein kinases. Proteins 68: 893-914.
8. Holden-Dye L, Walker RJ, (2007) Anthelmintic drugs. WormBook pp. 1-13.
9. Prichard RK, Geary TG, (2008) Drug discovery: fresh hope to can the worms. Nature 452: 157-158.
10. van den Enden E, (2009) Pharmacotherapy of helminth infection. Expert Opin Pharmacother 10: 435-451.
11. Doerig C, (2004) Protein kinases as targets for anti-parasitic chemotherapy. Biochim Biophys Acta 1697: 155-168.
12. Pollastri MP, Campbell RK, (2011) Target repurposing for neglected diseases. Future Med Chem 3: 1307-1315.
13. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
14. Pepin J, Milord F, Guern C, Schechter PJ, (1987) Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet 2: 1431-1433.
15. Ghedin E, Wang S, Spiro D, Caler E, Zhao Q, et al. (2007) Draft genome of the filarial nematode parasite Brugia malayi. Science 317: 1756-1760.
16. Abad P, Gouzy J, Aury JM, Castagnone-Sereno P, Danchin EG, et al. (2008) Genome sequence of the metazoan plant-parasitic nematode Meloidogyne incognita. Nat Biotechnol 26: 909-915.
17. Mitreva M, Jasmer DP, Zarlenga DS, Wang Z, Abubucker S, et al. (2011) The draft genome of the parasitic nematode Trichinella spiralis. Nat Genet 43: 228-235.
18. Brownlee DJ, Holden-Dye L, Walker RJ, (1997) Actions of the anthelmintic ivermectin on the pharyngeal muscle of the parasitic nematode, Ascaris suum. Parasitology 115: 553-561.
19. Jasmer DP, Yao C, Rehman A, Johnson S, (2000) Multiple lethal effects induced by a benzimidazole anthelmintic in the anterior intestine of the nematode Haemonchus contortus. Molecular and Biochemical Parasitology 105: 81-90.
20. Charvet CL, Robertson AP, Cabaret J, Martin RJ, Neveu C, (2012) Selective effect of the anthelmintic bephenium on Haemonchus contortus levamisole-sensitive acetylcholine receptors. Invert Neurosci 12: 43-51.
21. Brindley PJ, Mitreva M, Ghedin E, Lustigman S, (2009) Helminth genomics: The implications for human health. PLoS Negl Trop Dis 3: e538.
22. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, et al. (2006) A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 441: 91-95.
23. Morton S, Davis RJ, Cohen P, (2004) Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 572: 177-183.
24. Kamath A, Wang J, Lee F, Marathe P, (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemotherapy and Pharmacology 61: 365-376.
25. Christopher LJ, Cui D, Li W, Barros A, Arora VK, et al. (2008) Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys. Drug Metabolism and Disposition 36: 1341-1356.
26. Zhai S, Senderowicz A, Sausville E, Figg W, (2002) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. The Annals of Pharmacotherapy 36: 905-911.
27. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, et al. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Journal of Clinical Oncology 16: 2986-2999.
28. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, et al. (2001) A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer. Clinical Cancer Research 7: 1590-1599.
29. Shaikh B, Jackson J, Guyer G, Ravis WR, (1991) Determination of neomycin in plasma and urine by high-performance liquid chromatography. Application to a preliminary pharmacokinetic study. J Chromatogr 571: 189-198.
30. Zhuo X, Zheng N, Felix CA, Blair IA, (2004) KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM. Drug Metabolism and Disposition 32: 993-1000.
31. Kishi S, Yang W, Boureau B, Morand S, Das S, et al. (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103: 67-72.
32. Brooks DJ, Srinivas NR, Alberts DS, Thomas T, Igwemzie LM, et al. (1995) Phase I and pharmacokinetic study of etoposide phosphate. Anticancer Drugs 6: 637-644.
33. Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, et al. (1986) Etoposide pharmacokinetics in patients with normal and abnormal organ function. Journal of Clinical Oncology 4: 1690-1695.
34. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL, (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
35. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051.
36. Wei S, Marches F, Daniel B, Sonda S, Heidenreich K, et al. (2002) Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. Int J Parasitol 32: 969-977.
37. Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, et al. (2007) Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother 51: 4324-4328.
38. Gelmedin V, Caballero-Gamiz R, Brehm K, (2008) Characterization and inhibition of a p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis: antiparasitic activities of p38 MAPK inhibitors. Biochem Pharmacol 76: 1068-1081.
39. Brumlik MJ, Nkhoma S, Kious MJ, Thompson GR 3rd, Patterson TF, et al. (2011) Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. Exp Parasitol 128: 170-175.
40. Li B-W, Wang Z, Rush AC, Mitreva M, Weil GJ, (2012) Transcription profiling reveals stage-and function-dependent expression patterns in the filarial nematode Brugia malayi. BMC Genomics 13: 184.
41. Eglen RM, Reisine T, (2009) The current status of drug discovery against the human kinome. Assay Drug Dev Technol 7: 22-43.
42. Cheong JK, Virshup DM, (2011) Casein kinase 1: Complexity in the family. Int J Biochem Cell Biol 43: 465-469.
43. Urbaniak MD, (2009) Casein kinase 1 isoform 2 is essential for bloodstream form Trypanosoma brucei. Mol Biochem Parasitol 166: 183-185.
44. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, et al. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol 7: 411-422.
45. Calabokis M, Kurz L, Gonzatti MI, Bubis J, (2003) Protein kinase CK1 from Trypanosoma cruzi. J Protein Chem 22: 591-599.
46. Fong DH, Xiong B, Hwang J, Berghuis AM, (2011) Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PLoS One 6: e19589.
47. Murray P, Clegg RA, Rees HH, Fisher MJ, (2008) siRNA-mediated knockdown of a splice variant of the PK-A catalytic subunit gene causes adult-onset paralysis in C. elegans. Gene 408: 157-163.
48. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, et al. (2010) Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 15: 622-629.
49. Taoufiq Z, Gay F, Balvanyos J, Ciceron L, Tefit M, et al. (2008) Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J Infect Dis 197: 1062-1073.
50. Fischer P, Djoha S, Buttner DW, Zipfel PF, (2003) Isolation and characterization of the regulatory subunit of cAMP-dependent protein kinase from the filarial parasite Onchocerca volvulus. Mol Biochem Parasitol 128: 33-42.
51. Wurtz N, Chapus C, Desplans J, Parzy D, (2011) cAMP-dependent protein kinase from Plasmodium falciparum: an update. Parasitology 138: 1-25.
52. Li L, Stoeckert CJ Jr, Roos DS, (2003) OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res 13: 2178-2189.
53. Martin J, Abubucker S, Heizer E, Taylor CM, Mitreva M, (2012) Nematode.net update 2011: addition of data sets and tools featuring next-generation sequencing data. Nucleic Acids Res 40: D720-728.
54. Kumar S, Chaudhary K, Foster JM, Novelli JF, Zhang Y, et al. (2007) Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS One 2: e1189.
55. Taylor CM, Fischer K, Abubucker S, Wang Z, Martin J, et al. (2011) Targeting protein-protein interactions for parasite control. PLoS One 6: e18381.
56. Yook K, Harris TW, Bieri T, Cabunoc A, Chan J, et al. (2011) WormBase 2012: more genomes, more data, new website. Nucleic Acids Res 40 (Database issue):: D735-41.
57. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2009) InterPro: the integrative protein signature database. Nucleic Acids Res 37: D211-215.
58. Abubucker S, Martin J, Taylor CM, Mitreva M, (2011) HelmCoP: an online resource for helminth functional genomics and drug and vaccine targets prioritization. PLoS One 6: e21832.
59. Hillier LW, Reinke V, Green P, Hirst M, Marra MA, et al. (2009) Massively parallel sequencing of the polyadenylated transcriptome of C. elegans. Genome Res 19: 657-666.
60. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, et al. (2007) MINT: the Molecular INTeraction database. Nucleic Acids Research 35: D572-D574.
61. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T, (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432.
62. Warsow G, Greber B, Falk SS, Harder C, Siatkowski M, et al. (2010) ExprEssence-revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst Biol 4: 164.
63. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3: 33.
64. Rao R, Weil GJ, (2002) In vitro effects of antibiotics on Brugia malayi worm survival and reproduction. J Parasitol 88: 605-611.
65. Eddy SR, (1998) Profile hidden Markov models. Bioinformatics 14: 755-763.
66. Li BW, Rush AC, Jiang DJ, Mitreva M, Abubucker S, et al. (2011) Gender-associated genes in filarial nematodes are important for reproduction and potential intervention targets. PLoS Negl Trop Dis 5: e947.
67. DeLano LW (2006) PyMOL, version 1.2r1. Available: http://www.pymol.org. Accessed 25 September 2007.